Australia markets closed

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.20+0.63 (+8.32%)
At close: 04:00PM EST
8.25 +0.05 (+0.61%)
After hours: 07:59PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 671.47M
Enterprise value 520.44M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)4.73
Enterprise value/revenue N/A
Enterprise value/EBITDA -11.18

Trading information

Stock price history

Beta (5Y monthly) 0.82
52-week change 3-9.67%
S&P500 52-week change 316.58%
52-week high 311.93
52-week low 34.90
50-day moving average 36.17
200-day moving average 37.96

Share statistics

Avg vol (3-month) 31.02M
Avg vol (10-day) 31.35M
Shares outstanding 582.09M
Implied shares outstanding 682.09M
Float 879.5M
% held by insiders 13.19%
% held by institutions 133.90%
Shares short (14 Nov 2023) 418.12M
Short ratio (14 Nov 2023) 418.42
Short % of float (14 Nov 2023) 422.73%
Short % of shares outstanding (14 Nov 2023) 422.08%
Shares short (prior month 12 Oct 2023) 417.81M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 306 Oct 2015

Financial highlights

Fiscal year

Fiscal year ends 29 Sept 2023
Most-recent quarter (mrq)29 Sept 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-21.59%
Return on equity (ttm)-33.41%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
Net income avi to common (ttm)-47.51M
Diluted EPS (ttm)-0.60
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)151.02M
Total cash per share (mrq)1.84
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)12.32
Book value per share (mrq)1.73

Cash flow statement

Operating cash flow (ttm)-27.79M
Levered free cash flow (ttm)-14.27M